UK: New ILAP Will Involve Discussions On ‘Commercial Flexibilities’ For Innovative Products

The UK drug regulator has made a number of improvements to its innovative licensing and access pathway, including a more “core” role for National Health Service partners, which is expected to facilitate flexible commercial discussions around drug reimbursement.